Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

#4089

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Aim(s): To examine the impact of PRRT on outcome, hormonal symptoms and tryptophan metabolism in CS patients.

Materials and methods: Records from our ENETS Center of Excellence between 1995 and 2021 were screened for CS patients treated with PRRT. Overall survival (OS) and progression-free survival (PFS) were compared using Kaplan-Meier survival analysis and log-rank tests. Serum concentrations of tryptophan and its metabolites were determined via LC-MS/MS in patients undergoing PRRT.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,